Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 56 of 881 for:    "Reticulum Cell Sarcoma"

Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00028613
Recruitment Status : Completed
First Posted : June 30, 2003
Last Update Posted : January 9, 2014
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Case Comprehensive Cancer Center

Brief Summary:

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances such as radioactive iodine to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibodies in treating patients who have large cell lymphoma that has been previously treated.


Condition or disease Intervention/treatment Phase
Lymphoma Radiation: iodine I 131 monoclonal antibody Lym-1 Phase 1

Detailed Description:

OBJECTIVES:

  • Determine the maximum tolerated dose of iodine I 131 monoclonal antibody Lym-1 in patients with previously treated diffuse large cell lymphoma.
  • Determine the safety of this drug in these patients.
  • Determine the response of patients to this drug.

OUTLINE: This is a dose-escalation, multicenter study.

Patients receive unlabeled monoclonal antibody Lym-1 IV over 40 minutes followed 15-30 minutes later by iodine I 131 monoclonal antibody Lym-1 IV over 2 minutes.

Cohorts of 3-6 patients receive escalating doses of iodine I 131 monoclonal antibody Lym-1 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed weekly for 8 weeks and then every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 8-36 patients will be accrued for this study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Safety Study Of 131I-Lym-1 For The Treatment Of Previously Treated Diffuse Large B-Cell Lymphoma
Study Start Date : March 2001
Actual Primary Completion Date : October 2001
Actual Study Completion Date : October 2001






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Histologic diagnosis of B-cell diffuse large cell lymphoma (REAL classification system) confirmed by an independent central pathology reviewer.
  • The tumor's B-cell phenotype will be confirmed by positive L-26 (CD20).
  • Previous treatment with 2 common combination chemotherapy regimens. Patients previously treated with unlabeled monoclonal antibody therapy are eligible.
  • Men or women at least 18 years of age.
  • Karnofsky Performance Score (KPS) estimated to be > 60 at the time of the scheduled therapeutic dose of 131I-Lym-1.
  • Life expectancy estimated to be at least 3 months from the time of the therapeutic dose of 131I Lym-1.
  • Measurable disease demonstrable by physical examination or computerized tomography (CT).
  • CT scan evidence of at least one indicator lesion with at least one diameter that measures > 2 cm. (The CT scan should be done within 2 weeks of the imaging study.)

Exclusion Criteria

  • Inability or unwillingness to comply with the following:
  • Bone marrow biopsy
  • Return for follow-up visits
  • Remaining motionless for extended periods of time for imaging procedures
  • Serial blood/urine sampling (for dosimetry patients only)
  • Pregnancy (Women of childbearing potential must be practicing an effective method of contraception.)
  • Presence of a second malignancy except for basal cell skin carcinoma or carcinoma in-situ of the cervix
  • Presence of active lymphomatous meningitis or other CNS involvement with lymphoma.
  • HIV positive patients.
  • Prior total body irradiation, or a course of prior radiation > 3,000 cGy delivered to > 20% of the central marrow or the lumbar vertebrae within 6 months of screening.
  • Serum creatinine or total bilirubin > 2 x the upper limit of normal.
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase > 3 x the upper limit of normal.
  • Significant marrow lymphoma (defined as lymphoma cells constituting greater than 20% of the hematopoietic marrow elements from an iliac crest biopsy). A prior bone marrow biopsy is acceptable if it meets the following criteria:
  • If there is prior bone marrow involvement, the biopsy must be performed within 45 days of screening.
  • If there is no prior bone marrow involvement, the biopsy must be performed within 90 days of screening
  • WBC count < 3,500/mm3, granulocyte count < 1,500/mm3, or platelet count < 125,000/mm3.
  • Positive human anti-mouse antibodies (HAMA) serum values, defined as > 74 ng/mL at screening.
  • Patients who have not recovered from toxicities of most recent anti-lymphoma therapy.
  • Treatment with:
  • Colony stimulating factor G-CSF or GM-CSF within 120 hours of screening laboratory assessment.
  • Erythropoietin (EPO) within a month of screening laboratory assessment
  • Whole blood or platelet transfusion within 120 hours of screening laboratory assessment
  • History or electrocardiographic (ECG) evidence of Q-wave myocardial infarction within 6 months of screening or congestive heart failure (CHF; NYHA Stage III or IV).
  • Known hypersensitivity to iodine or iodine-containing organic substances.
  • Patients who require therapy with anticoagulants or antiplatelet drugs which cannot be discontinued during the study.
  • Patients who are known to have antiplatelet antibodies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00028613


Locations
Layout table for location information
United States, Ohio
Ireland Cancer Center
Cleveland, Ohio, United States, 44106-5065
Sponsors and Collaborators
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Study Chair: Omer N. Koc, MD Case Comprehensive Cancer Center

Layout table for additonal information
Responsible Party: Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00028613     History of Changes
Other Study ID Numbers: BRLX1400
CWRU-BRLX-1400
BRLX-303680
CWRU-090036
NCI-G01-2038
First Posted: June 30, 2003    Key Record Dates
Last Update Posted: January 9, 2014
Last Verified: January 2014
Keywords provided by Case Comprehensive Cancer Center:
recurrent adult diffuse large cell lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs